PACE Vape Messaging Study

Overview

The purpose of this study is to examine the effect of exposure to vape education messages on beliefs, perceptions, norms, and behaviors related to electronic vapor product use.

Full Title of Study: “Effects of Anti-JUUL-type Messages on Beliefs, Perceived Harms, and Behavioral Intentions Among Young Adults”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2020

Detailed Description

Using content developed from the formative research phase, participants in this randomized controlled trial will either be exposed to ten vape education messages or to ten messages on sun safety, with all messages formatted for social media.

This study will take place over a 1-month period. Individuals who complete the screening survey and are eligible to participate will be invited to complete a 10-15 minute baseline survey at the start of the study. This survey will ask questions about tobacco and electronic vapor product use, and beliefs about and perceptions of vape products. This survey will also ask about exposure to tobacco and e-cigarette marketing, exposure to prevention messaging on vaping and tobacco use, and peer and family influences on tobacco use. During the survey, participants will be presented with and be asked to provide feedback for short health-related messages.

One month after completing this survey, participants will be sent an invitation to the follow-up survey. This survey will again ask about tobacco and electronic vapor product use, and beliefs about and perceptions of vape products.

All study procedures will take place remotely, with surveys conducted online. At the end of the first survey, participants will be eligible to receive a $10 online gift card. Upon completion of the follow-up survey, participants will be eligible to receive a $15 online gift card. In total, participants will be eligible to receive up to $25 for completing both surveys. Those who are ineligible will not be asked to complete the baseline survey and will not be compensated.

Interventions

  • Behavioral: Vape Messaging Intervention
    • Participants will be exposed to 10 vape education messages

Arms, Groups and Cohorts

  • Experimental: Vape Messaging Intervention
    • Participants will be exposed to 10 vape education messages
  • No Intervention: Sun Safety Control
    • Participants will be exposed 10 sun safety messages

Clinical Trial Outcome Measures

Primary Measures

  • Nicotine/e-cigarette beliefs
    • Time Frame: Assessed at 1-month follow-up
    • True/false/don’t know questions about nicotine and electronic vapor/tobacco products
  • Vape harm perceptions
    • Time Frame: Assessed at 1-month follow-up
    • Harm perception questions about use of electronic vapor/vape products
  • Vaping-related norms
    • Time Frame: Assessed at 1-month follow-up
    • Questions (5-point Likert scale: 1=Very negative, 5 = Very positive) about others’ opinion of using electronic vapor/vape products like JUUL

Secondary Measures

  • Behavioral intentions
    • Time Frame: Assessed at 1-month follow-up
    • Questions about intent to use electronic vapor/vape products in the next 12 months

Participating in This Clinical Trial

Inclusion Criteria

  • Ages 18-24
  • Vermont resident
  • Access to a smartphone with internet
  • Use of one or more social media site(s) at least weekly

Exclusion Criteria

  • Aged 25 years or older
  • Not Vermont resident
  • No access to a smartphone with internet
  • Use of one or more social media site(s) less than weekly

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 24 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Vermont
  • Collaborator
    • National Institute on Drug Abuse (NIDA)
  • Provider of Information About this Clinical Study
    • Principal Investigator: Andrea Villanti, Associate Professor – University of Vermont
  • Overall Official(s)
    • Andrea C Villanti, PhD, MPH, Principal Investigator, University of Vermont
  • Overall Contact(s)
    • Elisha LePine, BA, (802) 391-0610, pace.vermont@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.